---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-037749"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:45:44.491028+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AbbVie amends revolver: commitments raised to $5.0B, maturity extended to 2028

## Summary
- Revolving credit facility commitments increased from $4.0B to $5.0B.
- Maturity date extended from August 27, 2024 to March 28, 2028.
- Facility remains unsecured; JPMorgan Chase continues as administrative agent.
- Second Amended and Restated Revolving Credit Agreement dated March 28, 2023.

## SEC filing metadata
- accession: 0001104659-23-037749
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/tm2310687d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-037749
- JSON: https://secwatch.observer/filing/0001104659-23-037749.json
- Plain text: https://secwatch.observer/filing/0001104659-23-037749.txt

## Key facts
- Debt Financings
  AbbVie Inc. amended revolving credit of $5.0 billion with JPMorgan Chase Bank, N.A. maturing March 28, 2028.
  - Instrument: revolving credit
  - Principal: $5.0 billion
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Maturity: March 28, 2028
  - Event: amendment
  source text: (i) increases the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and (ii) extends the maturity date of the facility from August 27, 2024 to March 28, 2028.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm
- Material Agreements
  AbbVie Inc. entered into Second Amended and Restated Revolving Credit Agreement with JPMorgan Chase Bank, N.A. valued at $5.0 billion (effective 2023-03-28).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Value: $5.0 billion
  - Effective: 2023-03-28
  source text: On March 28, 2023 (the “Effective Date”), AbbVie Inc. (“AbbVie”) entered into an amended and restated revolving credit agreement (the “Second Amended and Restated Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.